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Abstract 
A 45-year-old man complaining of cough, dyspnea, and difficulty in swallowing was 
referred to our hospital. Chest CT scan showed a mediastinal mass compressing the 
trachea. He was diagnosed with poorly differentiated lung carcinoma by percutaneous 
needle biopsy. Bronchoscopy and upper gastrointestinal endoscopy revealed a 
tracheoesophageal fistula (TEF). Long-lasting febrile neutropenia made it impossible to 
continue chemotherapy, but a course of radiotherapy (total 61 Gy) was completed. The 
next endoscopy revealed closure of the TEF. Chemoradiotherapy (CRT) has been reported 
to close TEF in esophageal cancer, but the risk of a CRT-induced worsening of the fistula 
has dissuaded physicians from using CRT to treat TEF in lung cancer patients. CRT may 
serve as a palliative treatment for TEF in lung cancer as well as esophageal cancer. 
 
Introduction 
Malignant tracheoesophageal fistula (TEF) is a serious complication of thoracic 
malignant diseases and is more common in esophageal cancer than in lung cancer [1]. 
TEF sometimes results in aspiration pneumonia, sepsis, and malnutrition associated with 
trouble in eating. Without proper and prompt treatment, life expectancy is estimated at 
about 6 weeks [1]. Stent intubation into the trachea and/or esophagus is a reliable 
treatment leading to improved quality of life [2]. Surgical bypass with gastrostomy is 
another option, though it might be too invasive in some patients with advanced cancer. 
Chemoradiotherapy (CRT) is a controversial option, as it has the potential to induce or Case Rep Oncol 2011;4:350–357 
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worsen TEF as a side effect, especially in lung cancer. In esophageal cancer, meanwhile, 
some reports have described closure of TEFs after CRT [3, 4]. 
Our group experienced a rare case of TEF that closed after CRT in a patient with 
poorly differentiated lung carcinoma. CRT seems to have good potential as a palliative 
treatment for TEF in lung cancer, as well.  
Case Report 
A 45-year-old man with complaints of cough, dyspnea, weight loss, and difficulty in swallowing was 
referred to our hospital. The symptoms had emerged 3 months earlier and he had been completely 
unable to eat for several days before his admission. On physical examination, a solid mass at the right 
neck was palpable, the right palpebral fissure was narrowed, and inspiratory stridor was auscultated. An 
enhanced chest CT scan revealed a small mass in the superior sulcus invading into the mediastinum 
(fig. 1). The sagittal view revealed a cavity within the mass and compression of the stenotic trachea by 
the mass, but there was no apparent communication between the esophagus and trachea. Laboratory 
data indicated mild normocytic anemia and elevated C-reactive protein. Among tumor markers, an 
elevation of cytokeratin 19 fragment and neuron-specific enolase (table 1) was noted. The patient was 
diagnosed with poorly differentiated lung carcinoma by percutaneous needle biopsy (fig. 2). The 
patient’s respiratory condition was too fragile to permit endoscopic examination at this point.  
Radiation therapy was commenced immediately, before confirmation of the pathological diagnosis, 
for fear of sudden asphyxiation by the occupying mass. Chemotherapy with cisplatin and docetaxel was 
added, but was discontinued when the patient developed febrile neutropenia requiring granulocyte-
stimulating factor and antibiotics for several days. When his respiratory condition improved enough to 
permit bronchoscopy and upper gastrointestinal endoscopy, these modalities revealed a hole with 
ulcerative edges in the trachea and upper esophagus (fig. 3). He was diagnosed with malignant TEF on 
that basis. We surmised that palliative treatment would prevent complications of TEF, such as 
aspiration pneumonia. In fact, the patient had already developed aspiration pneumonia during his 
hospital stay. As the fistula was located in the upper esophagus (20 cm below the incisive papilla), we 
anticipated that intubation of an expandable metallic stent to the esophagus would be deeply 
uncomfortable and intolerable. With airway stenting, an accidental insertion of the stent into the cavity 
inside the tumor was a concern. As the initial effect of radiation had improved the compression of the 
tumor to the trachea, the therapy was continued up to a total dose of 61 Gy. About 2 weeks after the 
radiation therapy was completed, the patient’s severe cough subsided for several days. Encouraged by 
the improvement, he attempted to eat sweets and managed to do so without coughing. A bronchoscopy 
a few days later revealed only one slit on the trachea, and upper gastrointestinal endoscopy showed a 
covering of normal epithelial tissue over the fistula (fig. 3). In the ensuing weeks he fully regained the 
ability to eat orally, his general condition improved remarkably, and he left our hospital. 
Discussion 
TEF is generally categorized as congenital or acquired. Traumas and malignancy, 
conditions that may be associated with side effects of CRT, are common causes of 
acquired TEF. As treatment, curative resection followed by repair of the trachea and/or 
esophagus is often chosen in congenital or non-malignant TEF [5]. Surgery is usually 
considered inappropriate in malignant TEF, as the patients tend to be in a bad condition 
and near the end of their lives. Esophageal bypass procedures for these patients have high 
morbidity and mortality. Palliative therapy should be the primary choice in terms of 
quality of life, and the therapeutic goals should be to restore the patency of the trachea by 
reducing the extrinsic compression and to enable these patients to take nutrition and fluid 
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Intubation of a stent to the tracheobronchial tree and/or esophagus is somewhat safer 
than the other procedures and good for symptomatic relief. Some papers report high 
success rates in double stenting [6]. When it is difficult to place a double stent at the same 
time, a tracheal stent has priority because an esophageal stent alone may compress the 
trachea and elicit respiratory distress [2]. We abandoned tracheal stenting in the current 
case for fear of a sudden impaction of the stent into the cavity. To avoid the risk of 
tracheal compression by the rapidly growing mediastinal tumor, we decided to administer 
CRT therapy in spite of the danger that the TEF would worsen.  
With recent progress in the treatment of advanced and/or metastatic non-small-cell 
lung cancer, molecular targeted agents such as gefitinib, erlotinib, and bevacizumab play 
significant roles in improving patient survival. But the standard therapy for locally 
advanced tumors not suited for surgery is radiotherapy combined with chemotherapy 
based on a platinum-containing drug. It remains controversial whether such agents 
should be added to radiotherapy in locally advanced cases [7]. Chemotherapy combined 
with the angiogenesis inhibitor bevacizumab, a monoclonal antibody to human vascular 
endothelial growth factor (VEGF), improves overall survival in colorectal cancer and non-
small-cell lung cancer [8, 9]. Although bevacizumab is recognized to be relatively safe, it is 
associated with the risk of hypertension, proteinuria, delayed wound healing, bowel 
perforation, and so on. A recent report suggests that bevacizumab added to CRT is 
associated with a higher incidence of TEF formation in both small-cell and non-small-cell 
lung carcinomas [10]. 
Most of the published papers on TEF usually address the condition in patients with 
esophageal cancer. Manabu et al. [11] reported that CRT brought about fistula closure in 
17 of 24 (70.8%) patients with esophageal cancer and led to restored oral alimentation in 
16 of those 17 (94.1%) patients. Esophageal tissues around the fistula appear to 
epithelialize in response to CRT, but the mechanisms behind this effect are unclear. The 
major pathology of esophagus cancer is squamous cell carcinoma, a tumor with relatively 
high radiosensitivity. We speculate that radiosensitivity might be critical in this 
phenomenon. In tissue repair, transforming growth factor-β (TGF-β) is a key cytokine 
that stimulates the production of surrounding extracellular matrix and heals the injured 
tissue [12]. Given that radiation often induces TGF-β signaling [13], we also speculate 
that this type of wound healing mechanism might underlie the epithelialization.  
TEF formation in lung carcinoma is rarely reported. To our knowledge, this is the first 
report of primary lung cancer with TEF successfully treated with CRT. The therapeutic 
agents for TEF should be selected by carefully considering the patient’s particular 
condition and the risk of aggravating the TEF. Though the usefulness and safety must be 
confirmed through further clinical research, CRT may prove to be effective as a palliative 
treatment for malignant TEF in lung cancer. 
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Table 1. Laboratory tests on admission 
 On  ad- 
mission 
Reference 
range 
White blood cells, /mm
3 5,700  3,900–8,800 
Differential count, %     
Neutrophils 76  28–70 
Lymphocytes 21  20–58 
Monocytes 1.0  0–12 
Eosinophils 2.0  0–5 
Red blood cells, ×10
4/mm
3 399  418–564 
Hemoglobin, g/dl  12.6  13.4–17.5 
Hematocrit, %  37.7  39.5–52.1 
Platelet count, ×10
4/mm
3 21.8  13.9–37.3 
Total protein, g/dl  7.2  6.8–8.3 
Albumin, g/dl  3.0  3.8–5.2 
Urea nitrogen, mg/dl  11.2  8.0–22.0 
Creatinine, mg/dl  0.65  0.30–1.20 
Sodium, mmol/l  146.5  134.0–150.0 
Potassium, mmol/l  3.8  3.5–5.0 
Chloride, mmol  107.4  98.0–108.0 
Calcium, mg/dl  9.2  8.7–11.0 
Lactate dehydrogenase, IU/l  602  107–220 
Alanine aminotransferase, IU/l  37  10–34 
Aspartate aminotransferase, IU/l  41  6–34 
Bilirubin total, mg/dl  0.49  0.22–1.20 
Glucose, mg/dl  81  60–110 
C-reactive protein, mg/dl  13.35  0.00–0.30 
Carcinoembryonic antigen, ng/ml  1.8  0.0–5.2 
Carbohydrate antigen 19-9, ng/ml  6.9  0.0–36.8 
Squamous cell carcinoma antigen, ng/ml  1.1  ≤1.5 
Cytokeratin 19 fragment, ng/ml  7.7  ≤3.5 
Progastrin-releasing peptide, pg/ml  32.7  ≤46.0 
Neuron-specific enolase, ng/ml  34  ≤10 
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Fig. 1. An enhanced chest CT scan shows a small mass in the superior sulcus with invasion into the 
mediastinum (a, b). The sagittal view reveals a cavity in the mass and compression of the stenotic 
trachea by the mass (c). 
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Fig. 2. Percutaneous needle biopsy specimen shows tumor cells with enlarged nuclei and scanty 
cytoplasm (HE, ×100). Immunohistochemically, the tumor cells are positive for CK-7 (b) and negative 
for CK-14 (c) and TTF-1 (d) (×400). 
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Fig. 3. Upper gastrointestinal endoscopy reveals the fistula located in the upper esophagus (a). 
Bronchoscopy shows a tracheal cavity communicating with the esophagus (b). A follow-up upper 
gastrointestinal endoscopy reveals a covering of epithelial tissue over the fistula (c), and bronchoscopy 
shows only one slit on the trachea (d). 
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